DCPH小分子靶向治疗公司被日本Ono收购24亿美元收购,公司核心资产包括QINLOCK(已上市,大中华权益授权给再鼎),23年销售1.6亿美元,用于治疗四线GIST胃肠道间质瘤:CSF1R抑制剂,肿瘤免疫治疗药物,临床三期,用于治疗TGCT腱滑膜巨细胞瘤 ;再次佩服再鼎的眼光。
Item...查看全文
SeekingBiotech04-29 20:24
$Deciphera(DCPH)$
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Deciphera Shareholders to Receive $25.60 per Share in Cash
小分子,精准治疗,24亿美金被日本巨头收购。查看全文
Deciphera(DCPH)05-10 19:35
$Deciphera(DCPH)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001654151-24-000018 Act: 34 Size: 5 MB 网页链接查看全文
Deciphera(DCPH)05-13 18:35
$Deciphera(DCPH)$ SC 14D9 Solicitation, recommendation statements Accession Number: 0001193125-24-136665 Act: 34 Size: 536 KB 网页链接查看全文
Deciphera(DCPH)05-07 05:25
$Deciphera(DCPH)$ SC TO-C Written communication relating to an issuer or third party Accession Number: 0001193125-24-132044 Act: 34 Size: 12 MB 网页链接查看全文
Deciphera(DCPH)06-12 08:35
$Deciphera(DCPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072195 Size: 14 KB 网页链接查看全文
Deciphera(DCPH)06-12 08:35
$Deciphera(DCPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072199 Size: 14 KB 网页链接查看全文
小飛俠愛投資2018-06-05 21:35
$Deciphera医药(DCPH)$ 提醒大家要小心附圖的人, 他天天收市後才發個股的買入價和賣出價, 那樣看他肯定必賺啊! 如果有天那個傻B給騙了提成就可憐了。 查看全文
蹊之美股生物医药2018-06-05 11:35
$Deciphera医药(DCPH)$
上图是DCPH$Deciphera医药(DCPH)$ 昨晚在ASCO公布的数据,非常的不错。在间质瘤指征上,2线用药的ORR为24%,DCR为80%(3个月)。而目前市场上的2线用药sunitinib的ORR为7%,DCR为60%,3线用药regorafenib的ORR为4.5%,DCR为53%。因此获批的可能大为增加。公司昨天大涨...查看全文
an小安2018-06-04 23:51
$Deciphera医药(DCPH)$ $Loxo Oncology, Inc. (LOXO)$ 本届ASCO亮眼的两家。 $内克塔疗法(NKTR)$ 失意人查看全文
蹊之美股生物医药2018-04-10 21:13
$Deciphera医药(DCPH)$ $Blueprint Medicines Corporation(BPMC)$ @今日话题 @雪盈证券
纳斯达克生物科技公司长文分析——激酶类抗肿瘤公司系列(一)
作者:格格;
微信公众号:蹊之美股生物医药;
雪球号:Caesar_Biotech;@今日话题,@雪盈证券
主要公司:Deciphera Phar...查看全文
淘沙见金2018-01-13 12:10
错过 $Blueprint Medicines Corporation(BPMC)$ , 还有 $Deciphera医药(DCPH)$ 可以考虑. @Stevevai1983查看全文
Replix锐璞美股2018-01-13 12:06
作者:淘沙见金 *本文由作者独家授权Replix锐璞生物医药研究发布
Deciphera Pharmaceuticals ($Deciphera医药(DCPH)$ ) 是一家来自美国马萨诸塞州的生物制药公司。这个公司成立于2003年,在2017年10月份完成IPO上市。公司专注于激酶抑制剂的抗癌药物研发,目前已开发了一系列针对各种癌症的小...查看全文
Replix锐璞美股2017-11-24 13:50
$Deciphera医药(DCPH)$ 同是做小分子激酶抑制剂的公司,Deciphera的头号在研产品DCC-2618跟$Blueprint Medicines Corporation(BPMC)$ 的头号明星产品BLU-285相比,优势跟劣势在哪里?详细分析请参考这篇文章:网页链接查看全文
Deciphera Pharmaceuticals(DCPH.US)周一宣布,日本小野药品工业(OPHLY.US)已同意以24亿美元的总股本价值收购这家癌症药物开发商。受此消息提振,截至发稿,Deciphera 盘前大涨71%。 据悉,小野药品工业... 网页链接
智通财经APP获悉,Deciphera Pharmaceutical(DCPH.US)今天宣布其在研药品vimseltinib在治疗腱鞘巨细胞瘤(TGCT)患者的MOTION关键3期试验的积极顶线结果,这些患者不适合进行手术治疗。分析显示,该试验达主要终点,vimseltinib治疗组患... 网页链接
$Deciphera(DCPH)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001828 Act: 33 Size: 1 KB 网页链接
$Deciphera(DCPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072221 Size: 24 KB 网页链接
$Deciphera(DCPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072223 Size: 18 KB 网页链接
$Deciphera(DCPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072214 Size: 12 KB 网页链接
$Deciphera(DCPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072215 Size: 14 KB 网页链接
$Deciphera(DCPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072220 Size: 21 KB 网页链接
$Deciphera(DCPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072218 Size: 16 KB 网页链接
$Deciphera(DCPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072209 Size: 17 KB 网页链接
$Deciphera(DCPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072206 Size: 17 KB 网页链接
$Deciphera(DCPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072208 Size: 20 KB 网页链接